Lantern Pharma’s drug development approach is innovative, using machine learning and A.I. to test and develop cancer treatments. From the novel small molecule compounds in our portfolio, to our targeted, rare patient populations who will benefit from these drugs, our pending and issued patent portfolio reflects our unique precision oncology focus.
Lantern Pharma actively manages a patent portfolio that includes over 80 issued patents and pending applications across 14 patent families. These patents stand as proof of our constant innovation using A.I. and machine learning to develop cancer treatments, and our focused dedication to the progress of oncology treatments.
General Application
RADR – Drug Discovery
Patent Summary
This is application is directed to method for identifying and stratifying drug treatments using subtypes identified using iterative process.
Countries
TBD
Priority Date
5/18/2020
General Application
RADR – Drug Discovery
Patent Summary
This is application is directed to method for identifying drug responsiveness using scoring of one or more binary mutations.
Countries
TBD
Priority Date
2/26/2021
General Application
RADR – Drug Discovery
Patent Summary
This is application is directed to method for identifying drug responsiveness using scoring of one or more binary mutations.
Countries
TBD
Priority Date
3/10/2022
General Application
HydroxyUreaMethyl Acylfulvene
Patent Title
Method for Treating Cancer with Acylfulvene and Radiation
Patent Summary
This is application is directed to methods for treating Cancers by administration of HydroxyUreaMethyl Acylfulvene with radiation doses.
Countries
TBD
Priority Date
11/18/2021
General Application
HydroxyUreaMethyl Acylfulvene
Patent Title
Method for Treating Leukemia and Blood Cancers
Patent Summary
This is application is directed to methods for treating Leukemia and Blood Cancers by administration of HydroxyUreaMethyl Acylfulvene.
Countries
TBD
Priority Date
5/03/2021
General Application
HydroxyUreaMethyl Acylfulvene
Patent Title
Method for Treating Breast Cancers and PARP Resistant Breast Cancers
Patent Summary
This is application is directed to methods for treating breast cancer and PARP resistant breast cancers by administration of HydroxyUreaMethyl Acylfulvene.
Countries
TBD
Priority Date
7/15/2022
General Application
HydroxyUreaMethyl Acylfulvene
Patent Title
Method for Treating Brain Metastases and CNS Metastases Using Illudins or HydroxyUreaMethyl Acylfulvene
Patent Summary
This is application is directed to methods for metastatic cancer by administration of HydroxyUreaMethyl Acylfulvene.
Countries
TBD
Priority Date
1/10/2021
General Application
HydroxyUreaMethyl Acylfulvene
Patent Title
Method for Treating Lung Cancer and Non-Small Cell Lung Cancer
Patent Summary
This is application is directed to methods for treating lung cancer and NSCLC by administration of HydroxyUreaMethyl Acylfulvene.
Countries
TBD
Priority Date
4/12/2021
General Application
HydroxyUreaMethyl Acylfulvene
Patent Title
Method for Treating Rhabdoid Tumors
Patent Summary
This is application is directed to methods for treating rhabdoid by administration of HydroxyUreaMethyl Acylfulvene.
Countries
TBD
Priority Date
12/29/2020
General Application
Positive HydroxyUreaMethyl Acylfulvene
Patent Title
Method For Treating Blood Cancers
Patent Summary
This is application is directed to methods for treating blood cancers by administration of (+)-HydroxyUreaMethyl Acylfulvene.
Countries
TBD
Priority Date
5/3/2021
General Application
HydroxyUreaMethyl Acylfulvene
Patent Title
Treating Cancers with Combinations of Spironolactone and Acylfulvenes
Patent Summary
This is application is directed to methods for treating cancer by administration of HydroxyUreaMethyl Acylfulvene and spironolactone.
Countries
TBD
Priority Date
7/29/2021
General Application
HydroxyUreaMethyl Acylfulvene
Patent Title
Treating Cancers with Combinations of PARP Inhibitor and Acylfulvenes
Patent Summary
This is application is directed to methods for treating cancer by administration of HydroxyUreaMethyl Acylfulvene and one or more PARP inhibitor.
Countries
TBD
Priority Date
7/29/2021
HydroxyUreaMethyl Acylfulvene
Method for Treating Pancreatic Cancer
This is application is directed to methods for treating pancreatic cancer by administration of HydroxyUreaMethyl Acylfulvene.
TBD
5/08/2020
HydroxyUreaMethyl Acylfulvene
Method for Treating Brain Cancer
This is application is directed to methods for treating brain tumor cancer (e.g., glioblastoma) by administration of HydroxyUreaMethyl Acylfulvene.
TBD
4/10/2020
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds
This application is directed to a method for (i) increasing patient survival time; (ii) promoting the arrest or retardation of tumor progression; (iii) concomitantly maintaining or increasing the quality of life in a cancer patient; and/or (iv) potentiating the cytotoxic/cytostatic effects of a chemotherapy agent or agents used to treat a patient suffering from cancer.
14675607 (Issue Fee Paid)
US
9/16/10
RADR Applications
Anticancer Drug Sensitivity-Determining Markers
This application is directed to a marker for use in determination of the sensitivity of a cancer patient to an anti-cancer agent (e.g., illudins) to be administered thereto, which marker can determine whether or not the cancer of the patient has a therapeutic response to the anti-cancer agent, and to application of the marker. Also included is a method for determining sensitivity of a subject having cancer to a illudin-based anti-cancer agent, the method includes measuring a level or presence of PTGR1 and at least one other gene.
PCT/US19/56039
US and other countries TBD
10/14/18
Next Generation Illudins
Illudin Analogs, Used Thereof, and Methods for Synthesizing the Same
This application is directed to illudin derivatives or analogs, intermediates, preparation methods, pharmaceutical compositions and uses thereof. A new and potentially more potent illudin is disclosed in this application.
PCT/US19/49555
US and other countries TBD
9/4/18
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Method for Treating Female Non Smokers with Non-Small Cell Lung Cancer
This application is directed to a method for increasing survival time in a female patient with non-small cell lung carcinoma or non-small cell lung carcinoma in which 2,2′-dithio-bis-ethane sulfonate or salt is administered in a therapeutically effective amount to the patient with non-small cell lung carcinoma.
PCT/US20/21615
US and other countries TBD
3/8/19
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Method for Treating Female Non Smokers with Non-Small Cell Lung Cancer
This application is directed to a method for increasing survival time in a female patient with non-small cell lung carcinoma or non-small cell lung carcinoma in which 2,2′-dithio-bis-ethane sulfonate or salt is administered in a therapeutically effective amount to the patient with non-small cell lung carcinoma.
PCT/US20/21615
US and other countries TBD
3/8/19
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Contemporaneous, Multiple Protein-Targeted Therapeutic Modification and/or Modulation of Disease by Administration of Sulfur-Containing, Amino Acid-Specific Small Molecules
This patent is directed to a method for the contemporaneous, heterogeneously-oriented metabolic modification and/or modulation of the expression level of multiple target molecules; wherein any combination of target molecules is selected from the group consisting of: anaplastic lymphoma kinase (ALK), mesenchymal epithelial transition (MET) kinase, the receptor tyrosine kinase (ROS1), epidermal growth factor receptor (EGFR), peroxiredoxin (Prx), excision repair cross-complementing protein 1 (ERCC1), insulin growth factor 1 receptor (IGF1R), ribonucleotide reductase, tubulin, farnesyltransferase, and other target molecules possessing a similar active site or structural motif.
14455855
US
8/8/14
LP-300
Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds
The patent is directed to increasing the survival time of cancer patients receiving LP-300 for cancers that are marked by overexpression of the regulatory proteins thioredoxin (TRX) or glutaredoxin (GRX) and/or exhibition of TRX- or GRX-mediated resistance to one or more chemotherapeutic interventions.
U.S. Patent No. 11,471,431
US Only
10/18/2022
Irofulven
Antitumor Agents
This application is directed to various acylfulvene analogs with various R groups thereon
US7141603
US Only
11/28/06
Irofulven
Illudin Analogs Useful as Anticancer Agents
This patent is directed to acylfulvene analogs, which inhibit tumor growth, especially solid tumor growth, and which have an adequate therapeutic index to be effective for in vivo treatment
US7655695
EP1909783B1 (Germany, France, and Great Britain), JP4989648 (US is Priority Application)
2/2/10
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Compounds and Methods for Reducing Undesired Toxicity of Chemotherapeutic Agents
This patent is directed to compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.
US7176192
Australia
10/26/01
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Anti-Cancer Activity Augmentation Compounds and Formulations & Methods of Use Thereof
This patent is directed to methods for augmentation of anti-cancer activity
China ZL200780017354
China, Australia
3/16/07
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Method for Treating Cancer Having Greater Efficacy and Reduced Adverse Effects
This patent is direct to reducing side effects with disulfide or thiol-containing compound .
US6596320
US
1/11/02
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Process for Synthesizing Pharmaceutically Active Disulfide Salts
This patent is directed to a process for synthesizing pharmaceutically active disulfide or thiol-containing compound
US6504049
Australia, Canada, Denmark, France, Germany, Ireland, Italy, Japan, Netherlands, Spain, Sweden, Switzerland, UK and US
5/30/02
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Drugs for Prophylaxis or Mitigation of Taxane-Induced Neuropathies
This Patent covering treating taxane neuropathy with 2,2_-dithiobis ethane sulfonate
US8710095
Australia, France, Germany, Japan, Spain, Sweden, Switzerland, UK and US
4/30/02
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Method For Preparing Disodium 2,2′-Dithiobis(Ethanesulfonate)
This patent is direct to a method for preparing Disodium 2,2′-Dithiobis(Ethanesulfonate)
US6936733
Australia, Belgium, France, Germany, Ireland, Italy, Japan, Sweden, Switzerland, UK and US
7/17/01
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Compounds and Methods for Reducing Undesired Toxicity of Chemotherapeutic Agents
The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.
US Patent Nos. 7829540, 7829539, 7829117, 7829538 & 7235589
France, UK and US
11/14/07
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Method of Treating Patients Undergoing Kidney Dialysis
This invention relates to a method of treating patients who are receiving dialysis treatments. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.
US7235589
France, UK and US
9/21/05
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Process for Synthesizing Disulfides
This patent discloses a process for producing a substantially pure disulfide , such as disodium 2,2_-dithiobis ethane sulfonate, by an efficient procedure from available, relatively inexpensive raw materials.
US7053240
Australia, Canada, China
12/17/04
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Chemoprotective Methods and Compositions
Compositions and methods for reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, for example, one or more chemotherapy-associated toxicities in a subject receiving one or more chemotherapeutic agents.
CA2648945
Australia, Canada, China, Denmark, France, Germany, Hungary, Ireland, Italy, Japan, Netherlands, Sweden, Switzerland, and UK
12/13/06
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Treatment Methods and Compositions for Lung Cancer, Adenocarcinoma, and Other Medical Conditions
This patent is directed to an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions
US9320760
Australia, Canada, China, Denmark, France, Germany, Japan, Netherlands, Sweden, Switzerland, UK, and US
7/15/08
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Medicinal Disulfide Salts
This patent is directed to various medicinal disulfide salts
US7282602
Canada, Japan, Mexico, and US
9/21/04
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Treatment Methods and Compositions for Lung Cancer, Adenocarcinoma, and Other Medical Conditions
This patent is directed to an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions
US9320760
Australia, Canada, China, Denmark, France, Germany, Japan, Netherlands, Sweden, Switzerland, UK, and US
7/15/08
Disodium 2,2’-dithio-bis-ethane sulfonate (dimensa)
Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds
This patent is directed to an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions
US9023805
US
9/16/10
By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
